Tariket S, Sut C, Hamzeh-Cognasse H, Laradi S, Garraud O, Cognasse F
Université de Lyon, GIMAP-EA3064, 42100 Saint-Étienne, France; Établissement français du sang Rhône-Alpes-Auvergne, 42100 Saint-Étienne, France.
Université de Lyon, GIMAP-EA3064, 42100 Saint-Étienne, France.
Transfus Clin Biol. 2018 Sep;25(3):204-209. doi: 10.1016/j.tracli.2018.03.006. Epub 2018 Apr 7.
Even though used systematically with leukocyte reduction, platelet transfusions still cause adverse reactions in recipients. They include Transfusion-Related Acute Lung Injury (TRALI), respiratory distress that occurs within six hours of the transfusion. The pathophysiology of this transfusion complication brings complex cellular communication into play. The role, particularly inflammatory, played by blood platelets in TRALI pathophysiology has been demonstrated, but is still under debate. Blood platelets play a role in inflammation, particularly via the CD40/CD40L (sCD40L) immunomodulator complex. In this study, we examine in particular the specific involvement of the CD40/CD40L (sCD40L) complex in the inflammatory pathogenesis of TRALI. This molecular complex could be a major target in a TRALI prevention strategy. Improving the conditions in which the platelet concentrates (PC) are prepared and stored would contribute to controlling partly the risks of non-immune TRALI.
尽管在使用白细胞滤除技术的情况下系统性地进行血小板输注，但仍会在受血者中引发不良反应。这些反应包括输血相关急性肺损伤（TRALI），即在输血后六小时内出现的呼吸窘迫。这种输血并发症的病理生理学涉及复杂的细胞通讯。血小板在TRALI病理生理学中所起的作用，尤其是炎症方面的作用，已得到证实，但仍存在争议。血小板在炎症中发挥作用，特别是通过CD40/CD40L（可溶性CD40L）免疫调节复合物。在本研究中，我们特别研究了CD40/CD40L（可溶性CD40L）复合物在TRALI炎症发病机制中的具体作用。这种分子复合物可能是TRALI预防策略的主要靶点。改善血小板浓缩物（PC）的制备和储存条件将有助于部分控制非免疫性TRALI的风险。
